Physician profile
Michael K Wang
NPI 1124373683
$948.27
in general payments reported to CMS, 2019-2025
18 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $119 · 2021: $73.77 · 2022: $43.72 · 2023: $157 · 2024: $272 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566 · Education: $6.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.28 |
| Education | $6.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $210.80 | 2019-2024 | Linzess |
| Sunovion Pharmaceuticals INC. | $205.92 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $121.61 | 2023 | Smoflipid |
| Qol Medical, LLC | $78.60 | 2021-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $52.51 | 2021-2025 | Eohilia |
| Albireo Pharma, INC. | $49.63 | 2024 | Bylvay |
| Sandoz INC. | $39.36 | 2024 | Hyrimoz |
| Nestle Healthcare Nutrition INC. | $31.93 | 2022-2023 | |
| Genzyme Corporation | $23.94 | 2022 | |
| Kyowa Kirin, INC. | $23.52 | 2025 | |
| Mirum Pharmaceuticals, INC. | $22.80 | 2025 | Livmarli |
| Celltrion USA INC. | $22.74 | 2024 | Zymfentra |
| Rhythm Pharmaceuticals, INC. | $20.67 | 2025 | Imcivree |
| Travere Therapeutics, INC. | $18.32 | 2021-2023 | Cholbam |
| Concordia Pharmaceuticals INC. | $13.23 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $12.69 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.